<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:18:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9150146" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9150146</identifier>
        <datestamp>2022-05-31</datestamp>
        <setSpec>sageopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Psychopharmacol</journal-id>
              <journal-id journal-id-type="publisher-id">JOP</journal-id>
              <journal-id journal-id-type="hwp">spjop</journal-id>
              <journal-title-group>
                <journal-title>Journal of Psychopharmacology (Oxford, England)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0269-8811</issn>
              <issn pub-type="epub">1461-7285</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage UK: London, England</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9150146</article-id>
              <article-id pub-id-type="pmcid">PMC9150146</article-id>
              <article-id pub-id-type="pmc-uid">9150146</article-id>
              <article-id pub-id-type="pmid">35443830</article-id>
              <article-id pub-id-type="pmid">35443830</article-id>
              <article-id pub-id-type="doi">10.1177/02698811221089032</article-id>
              <article-id pub-id-type="publisher-id">10.1177_02698811221089032</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Short Report</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Catechol-O-methyltransferase activity does not influence emotional processing in men</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0108-1327</contrib-id>
                  <name>
                    <surname>Martens</surname>
                    <given-names>Marieke AG</given-names>
                  </name>
                  <xref rid="aff1-02698811221089032" ref-type="aff">1</xref>
                  <xref rid="aff2-02698811221089032" ref-type="aff">2</xref>
                  <xref rid="fn1-02698811221089032" ref-type="author-notes">*</xref>
                  <xref rid="corresp1-02698811221089032" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dalton</surname>
                    <given-names>Nina</given-names>
                  </name>
                  <xref rid="aff1-02698811221089032" ref-type="aff">1</xref>
                  <xref rid="fn1-02698811221089032" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scaife</surname>
                    <given-names>Jessica</given-names>
                  </name>
                  <xref rid="aff1-02698811221089032" ref-type="aff">1</xref>
                  <xref rid="aff2-02698811221089032" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harmer</surname>
                    <given-names>Catherine J</given-names>
                  </name>
                  <xref rid="aff1-02698811221089032" ref-type="aff">1</xref>
                  <xref rid="aff2-02698811221089032" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6719-1126</contrib-id>
                  <name>
                    <surname>Harrison</surname>
                    <given-names>Paul J</given-names>
                  </name>
                  <xref rid="aff1-02698811221089032" ref-type="aff">1</xref>
                  <xref rid="aff2-02698811221089032" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2966-2281</contrib-id>
                  <name>
                    <surname>Tunbridge</surname>
                    <given-names>Elizabeth M</given-names>
                  </name>
                  <xref rid="aff1-02698811221089032" ref-type="aff">1</xref>
                  <xref rid="aff2-02698811221089032" ref-type="aff">2</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1-02698811221089032"><label>1</label>Department of Psychiatry, University of Oxford, Oxford, UK</aff>
              <aff id="aff2-02698811221089032"><label>2</label>Oxford Health NHS Foundation Trust, Oxford, UK</aff>
              <author-notes>
                <corresp id="corresp1-02698811221089032">Marieke AG Martens, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK. Email: <email>marieke.martens@psych.ox.ac.uk</email></corresp>
                <fn fn-type="equal" id="fn1-02698811221089032">
                  <label>*</label>
                  <p>These authors contributed equally to this work</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2022</year>
              </pub-date>
              <volume>36</volume>
              <issue>6</issue>
              <fpage>768</fpage>
              <lpage>775</lpage>
              <permissions>
                <copyright-statement>© The Author(s) 2022</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <sec id="section1-02698811221089032">
                  <title>Background:</title>
                  <p>Catechol-O-methyltransferase (COMT) regulates cortical dopaminergic transmission and prefrontal-dependent cognitive function. However, its role in other cognitive processes, including emotional processing, is relatively unexplored. We therefore investigated the separate and interactive influences of COMT inhibition and Val<sup>158</sup>Met (rs4680) genotype on performance on an emotional test battery.</p>
                </sec>
                <sec id="section2-02698811221089032">
                  <title>Methods:</title>
                  <p>We recruited 74 healthy men homozygous for the functional COMT Val<sup>158</sup>Met polymorphism. Volunteers were administered either a single 200 mg dose of the brain-penetrant COMT inhibitor tolcapone or placebo in a double-blind, randomised manner. Emotional processing was assessed using the emotional test battery, and mood was rated using visual analogue scales and the Profile of Mood States (POMS) questionnaire across the test day.</p>
                </sec>
                <sec id="section3-02698811221089032">
                  <title>Results:</title>
                  <p>There were no main or interactive effects of Val<sup>158</sup>Met genotype or tolcapone on any of the emotional processing measures or mood ratings.</p>
                </sec>
                <sec id="section4-02698811221089032">
                  <title>Conclusions:</title>
                  <p>Our findings suggest that, at least in healthy adult men, COMT has little or no effect on emotional processing or mood. These findings contrast with several neuroimaging studies that suggest that COMT modulates neural activity during emotional processing. Thus, further studies are required to understand how COMT impacts on the relationship between behavioural output and neural activity during emotional processing. Nevertheless, our data suggest that novel COMT inhibitors under development for treating cognitive dysfunction are unlikely to have acute off target effects on emotional behaviours.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Dopamine</kwd>
                <kwd>tolcapone</kwd>
                <kwd>mood</kwd>
                <kwd>cognition</kwd>
                <kwd>antidepressant</kwd>
                <kwd>emotional processing</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="award1-02698811221089032">
                  <funding-source id="funding1-02698811221089032">
                    <institution-wrap>
                      <institution>Medical Research Council</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000265</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding1-02698811221089032">MR/K013092/1</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section5-02698811221089032">
              <title>Introduction</title>
              <p>Dopaminergic abnormalities are prominent in many psychiatric disorders and contribute substantially to their cognitive and emotional components (<xref rid="bibr18-02698811221089032" ref-type="bibr">Figee et al., 2016</xref>; <xref rid="bibr25-02698811221089032" ref-type="bibr">Goldman-Rakic et al., 2004</xref>). The catechol-O-methyltransferase (COMT) enzyme metabolises dopamine in the prefrontal cortex (PFC) (<xref rid="bibr4-02698811221089032" ref-type="bibr">Byers et al., 2020</xref>; <xref rid="bibr61-02698811221089032" ref-type="bibr">Tunbridge, 2004</xref>). The human <italic toggle="yes">COMT</italic> gene contains a functional polymorphism (Val<sup>158</sup>Met; rs4680) that influences enzyme activity: the ancestral Val<sup>158</sup> allele has ~40% greater activity than the Met<sup>158</sup> allele (<xref rid="bibr62-02698811221089032" ref-type="bibr">Tunbridge et al., 2019</xref>). COMT activity can also be altered pharmacologically by COMT inhibitors, licenced for the adjunctive treatment of Parkinson’s disease (<xref rid="bibr68-02698811221089032" ref-type="bibr">Zürcher et al., 1990</xref>).</p>
              <p>An inverted-U-shaped relationship exists between dopamine and PFC-dependent cognitive function, whereby either too little or too much dopamine signalling impairs cognitive performance (<xref rid="bibr24-02698811221089032" ref-type="bibr">Goldman-Rakic, 2000</xref>; <xref rid="bibr65-02698811221089032" ref-type="bibr">Williams and Goldman-Rakic, 1995</xref>). Separately, both COMT inhibition (with the brain-penetrant COMT inhibitor tolcapone) and the Met<sup>158</sup> allele are associated with improved PFC dopamine-dependent cognitive task performance, compared with placebo and the Val<sup>158</sup> allele, respectively (<xref rid="bibr2-02698811221089032" ref-type="bibr">Barkus et al., 2016</xref>; <xref rid="bibr4-02698811221089032" ref-type="bibr">Byers et al., 2020</xref>; <xref rid="bibr16-02698811221089032" ref-type="bibr">Farrell et al., 2012</xref>; <xref rid="bibr19-02698811221089032" ref-type="bibr">Gasparini et al., 1997</xref>; <xref rid="bibr57-02698811221089032" ref-type="bibr">Tan et al., 2007</xref>; <xref rid="bibr58-02698811221089032" ref-type="bibr">Troudet et al., 2016</xref>; <xref rid="bibr61-02698811221089032" ref-type="bibr">Tunbridge, 2004</xref>). Furthermore, and consistent with the inverted-U relationship, COMT genotype and tolcapone have interactive effects: COMT inhibition improves cognition in individuals with high COMT activity (e.g. Val<sup>158</sup> homozygotes) but has less effect, or may even impair, cognition in those with low COMT activity (e.g. Met<sup>158</sup> homozygotes) (<xref rid="bibr2-02698811221089032" ref-type="bibr">Barkus et al., 2016</xref>; <xref rid="bibr16-02698811221089032" ref-type="bibr">Farrell et al., 2012</xref>; <xref rid="bibr20-02698811221089032" ref-type="bibr">Giakoumaki et al., 2008</xref>). Given these findings, COMT inhibitors with more optimal properties are under active development for the treatment of cognitive dysfunction in schizophrenia and other disorders (<xref rid="bibr4-02698811221089032" ref-type="bibr">Byers et al., 2020</xref>; <xref rid="bibr54-02698811221089032" ref-type="bibr">Su et al., 2021</xref>). However, COMT’s significance for clinically relevant domains other than executive cognition remains largely unexplored (<xref rid="bibr7-02698811221089032" ref-type="bibr">DeBrosse et al., 2020</xref>; <xref rid="bibr36-02698811221089032" ref-type="bibr">Korn et al., 2021</xref>; <xref rid="bibr59-02698811221089032" ref-type="bibr">Tunbridge et al., 2012</xref>) and may have significance for understanding potential additional indications or side effects for these novel compounds.</p>
              <p>Several lines of evidence suggest that COMT may influence emotional processing. Dopamine modulates brain regions implicated in the processing of emotional sensory information including the PFC, basolateral amygdala and nucleus accumbens (<xref rid="bibr27-02698811221089032" ref-type="bibr">Gordon-Fennell and Stuber, 2021</xref>; <xref rid="bibr28-02698811221089032" ref-type="bibr">Grace and Rosenkranz, 2002</xref>; <xref rid="bibr33-02698811221089032" ref-type="bibr">Karreman and Moghaddam, 1996</xref>), and dopamine agonism is a potential therapeutic approach for the treatment of mood disorders (<xref rid="bibr13-02698811221089032" ref-type="bibr">Dunlop and Nemeroff, 2007</xref>; <xref rid="bibr49-02698811221089032" ref-type="bibr">Romeo et al., 2018</xref>). Evidence from both human and animal studies demonstrates that COMT genotype influences aspects of emotional processing. Neuroimaging studies demonstrate consistent associations between the COMT Val<sup>158</sup>Met polymorphism and brain activation (determined using fMRI) during emotional processing: the Met<sup>158</sup> allele is associated with greater limbic brain activation (including hippocampus, amygdala and PFC) in response to negatively valanced stimuli (<xref rid="bibr12-02698811221089032" ref-type="bibr">Drabant et al., 2006</xref>; <xref rid="bibr43-02698811221089032" ref-type="bibr">Mier et al., 2010</xref>; <xref rid="bibr48-02698811221089032" ref-type="bibr">Rasch et al., 2010</xref>; <xref rid="bibr50-02698811221089032" ref-type="bibr">Smolka, 2005</xref>; <xref rid="bibr51-02698811221089032" ref-type="bibr">Smolka et al., 2007</xref>; <xref rid="bibr66-02698811221089032" ref-type="bibr">Williams et al., 2010</xref>; although see <xref rid="bibr34-02698811221089032" ref-type="bibr">Kempton et al., 2009</xref>, who found greater limbic activation in Val<sup>158</sup> vs Met<sup>158</sup> homozygotes). Caution should be exercised when extrapolating simple differences in fMRI signal to underlying psychological processes; nevertheless, these findings are broadly consistent with a model in which the Met<sup>158</sup> allele confers greater attention and/or sensitivity to negative emotional information, compared to the Val<sup>158</sup> allele. This hypothesis is consistent with reported associations between the Met<sup>158</sup> allele and risk for various anxiety and stress-related disorders (<xref rid="bibr11-02698811221089032" ref-type="bibr">Domschke et al., 2004</xref>; <xref rid="bibr35-02698811221089032" ref-type="bibr">Kolassa et al., 2010</xref>; <xref rid="bibr47-02698811221089032" ref-type="bibr">Pooley et al., 2007</xref>). However, findings from behavioural studies are more mixed. Thus, while in some mouse models, lower COMT activity is associated with increased anxiety-like behaviours (<xref rid="bibr22-02698811221089032" ref-type="bibr">Gogos et al., 1998</xref>; <xref rid="bibr46-02698811221089032" ref-type="bibr">Papaleo et al., 2008</xref>), this is not seen for all COMT models (<xref rid="bibr2-02698811221089032" ref-type="bibr">Barkus et al., 2016</xref>). Findings in human volunteers are also inconsistent: while some studies report exaggerated responses to negative stimuli and greater negative biases in processing emotional stimuli associated with the Met<sup>158</sup>, compared with the Val<sup>158</sup>, allele (<xref rid="bibr23-02698811221089032" ref-type="bibr">Gohier et al., 2014</xref>; <xref rid="bibr26-02698811221089032" ref-type="bibr">Gong et al., 2013</xref>; <xref rid="bibr44-02698811221089032" ref-type="bibr">Montag et al., 2008</xref>), others have reported the opposite pattern (<xref rid="bibr64-02698811221089032" ref-type="bibr">Weiss et al., 2007</xref>) or have found no genotype differences in emotional processing (<xref rid="bibr5-02698811221089032" ref-type="bibr">Carrà et al., 2017</xref>; <xref rid="bibr8-02698811221089032" ref-type="bibr">Defrancesco et al., 2011</xref>; <xref rid="bibr34-02698811221089032" ref-type="bibr">Kempton et al., 2009</xref>).</p>
              <p>To our knowledge, no studies have examined the impact of COMT inhibition on emotional processing in human participants or whether its effects interact with genotype (and, if so, whether this also follows an inverted-U). However, in our earlier study, we found that tolcapone increased visual analogue score ratings of ‘happiness’ in Val<sup>158</sup> but not Met<sup>158</sup> individuals (<xref rid="bibr59-02698811221089032" ref-type="bibr">Farrell et al., 2012</xref>). Further hints of a potential impact of COMT inhibition on emotional processing come from a small, open clinical trial that provided preliminary evidence that tolcapone might have antidepressant potential (<xref rid="bibr17-02698811221089032" ref-type="bibr">Fava et al., 1999</xref>).</p>
              <p>Taken together, the available data suggest that COMT genotype influences limbic activation during emotional processing; however, effects on emotional behaviour are not clear-cut. Furthermore, although there are hints that COMT inhibition may positively impact on mood, these findings are preliminary and in need of replication. It is also not known if or how these effects differ based on COMT genotype. This study, therefore, aimed to comprehensively assess the impact of COMT genotype and COMT inhibition on emotional processing. To achieve this, we investigated the separate and interactive effects of COMT inhibition and Val<sup>158</sup>Met genotype on emotional processing in healthy men, using an emotional test battery which tests multiple dimensions of emotional behaviours and is sensitive to antidepressant actions (<xref rid="bibr29-02698811221089032" ref-type="bibr">Harmer et al., 2011</xref>).</p>
            </sec>
            <sec sec-type="methods" id="section6-02698811221089032">
              <title>Methods</title>
              <p>We performed a double-blind, randomised, placebo-controlled, experimental medicine study that investigated non-smoking healthy males homozygous for the COMT Val<sup>158</sup>Met polymorphism. The study’s design paralleled that of our study of tolcapone’s effects on working memory (<xref rid="bibr16-02698811221089032" ref-type="bibr">Farrell et al., 2012</xref>).</p>
              <sec id="section7-02698811221089032">
                <title>Participants</title>
                <p>Ethical approval for this study was granted by the South Central – Berkshire Research Ethics Committee (REC number: 14 SC 0035). All participants gave written informed consent.</p>
                <p>Non-smoking, healthy men aged 18–45 years old were recruited by advertisement. Women were excluded from the study given marked sexually dimorphic effects of COMT (<xref rid="bibr32-02698811221089032" ref-type="bibr">Harrison and Tunbridge, 2008</xref>; <xref rid="bibr37-02698811221089032" ref-type="bibr">Laatikainen et al., 2013</xref>). To identify homozygotes, males who expressed initial interest in the study were mailed study packs and provided buccal swabs by post. All returned samples were genotyped for the COMT Val<sup>158</sup>Met polymorphism (rs4680) using the appropriate Taqman SNP Genotyping Assay.</p>
                <p>Potential participants (homozygotes), who were still interested in taking part, underwent telephone screening to establish inclusion and exclusion criteria. Mental health was assessed using the Structured Clinical Interview for <italic toggle="yes">DSM-IV</italic> (<italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic>). Exclusion criteria were a current or past history of psychiatric or neurological disorder, use of psychotropic medication, alcohol intake greater than 30 units/week, illicit drug use in the last 3 months or an inadequate command of spoken English. Due to the small risk of hepatotoxicity accompanying tolcapone use, participants were also questioned about their medical history and whether they had any history of liver disease. The participants’ general practitioners were asked to check that participants did not meet any of the exclusion criteria and that there were no medical reasons why it would be unsafe for them to take part in the study.</p>
                <p>In all, 369 males were genotyped; genotypes were in Hardy–Weinberg equilibrium (<italic toggle="yes">n</italic> = 90 Val<sup>158</sup>/Val<sup>158</sup>; <italic toggle="yes">n</italic> = 198 Val<sup>158</sup>/Met<sup>158</sup> and <italic toggle="yes">n</italic> = 81 Met<sup>158</sup>/Met<sup>158</sup>; χ<sup>2</sup> = 2.01; <italic toggle="yes">p</italic> = 0.156). Not all genotyped homozygotes accepted the subsequent screening invitation, and not all proved eligible after completion of screening. A total of 74 men were recruited, to match the sample size of our previous study (<xref rid="bibr16-02698811221089032" ref-type="bibr">Farrell et al., 2012</xref>), and randomised (by P.J.H.) to receive either placebo or tolcapone. The participants and the main study researchers (J.S., N.D. and M.A.G.M.) were blind to both genotype and drug allocation.</p>
              </sec>
              <sec id="section8-02698811221089032">
                <title>Study design</title>
                <p>Participants attended the laboratory for testing at 9.15 a.m. Upon arrival, they were reminded of the study details and their right to withdraw. Once consent had been reaffirmed, participants were asked to complete the National Adult Reading Test (NART – a measure of verbal IQ), along with the State-Trait Anxiety Inventory (STAI) (<xref rid="bibr53-02698811221089032" ref-type="bibr">Spielberger, 1983</xref>). Furthermore, baseline measures of mood were taken by using the Profile of Mood States (POMS) questionnaire (<xref rid="bibr41-02698811221089032" ref-type="bibr">McNair et al., 1971</xref>) and visual analogue scales (VAS – rating alertness, drowsiness, anxiety, sadness, happiness and nausea). After participants had completed these initial paper measures, they were given a tolcapone tablet (200 mg) or visually matched placebo by mouth. Tolcapone has an elimination half-life of 2.0 ± 0.8 h; the dose given produces 70–80% peripheral blood COMT inhibition between 1 and 4 h (<xref rid="bibr6-02698811221089032" ref-type="bibr">Ceravolo et al., 2002</xref>; <xref rid="bibr9-02698811221089032" ref-type="bibr">Dingemanse et al., 1995</xref>) and influences cognitive function within this period (<xref rid="bibr59-02698811221089032" ref-type="bibr">Tunbridge et al., 2012</xref>). Therefore, testing commenced 90 min after administration and was completed within 4 h.</p>
                <p>Participants completed the emotional test battery (<xref rid="bibr31-02698811221089032" ref-type="bibr">Harmer et al., 2004</xref>), a behavioural test battery that has previously shown to be sensitive to detect biases in emotional processing. The POMS and VAS were repeated three more times during the test day: at 1.5 h and 3.5 h after tablet administration and once testing was completed. However, due to experimenter error, data for the 1.5 h and 3.5 h timepoints were incomplete, and so, only data from the pre- and post-testing timepoints are presented here.</p>
              </sec>
              <sec id="section9-02698811221089032">
                <title>Tasks</title>
                <p>The emotional test battery comprised four validated, computerised cognitive tasks designed to assess the processing of a variety of emotionally valanced stimuli. It is sensitive to the negative biases in emotional processing observed in depression and to the early effects of antidepressants on emotional processing (<xref rid="bibr30-02698811221089032" ref-type="bibr">Harmer et al., 2009</xref>). The order of administration was as follows: Facial Expression Recognition Task (FERT), Emotional Categorisation Task (ECAT), Faces Dot Probe Task (FDOT) and Emotional Recall Task (EREC).</p>
                <sec id="section10-02698811221089032">
                  <title>Facial Expression Recognition Task (FERT)</title>
                  <p>Participants were presented with pictures of human facial expressions. Each face displayed one of six basic emotions (anger, disgust, fear, happiness, sadness or surprise). Each emotional expression was presented at different levels of intensity (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 100%), which have been created by combining shape and texture features of the two extremes ‘neutral’ (i.e. 0%) and ‘full prototypical emotion’ (i.e. 100%) to varying degrees (<xref rid="bibr67-02698811221089032" ref-type="bibr">Young et al., 1997</xref>). In total, four examples of each emotion at each intensity level were presented. Emotions were displayed by 10 different individuals overall, and for each of the 10 individuals, a neutral facial expression was presented as well. Thus, 250 stimulus presentations (6 emotions × 10 intensities × 4 examples + 10 neutral faces) were used in total. Facial expressions were presented in a random order on a computer screen for approximately 500 ms, followed by a blank black screen. Participants were instructed to correctly classify each facial expression as quickly and as accurately as possible. Responses were made by pushing one out of seven labelled buttons on a keyboard. The main outcomes of interest were accuracy, misclassifications and averaged reaction time for correct classifications.</p>
                </sec>
                <sec id="section11-02698811221089032">
                  <title>Emotional Categorisation Task (ECAT)</title>
                  <p>The ECAT comprises a series of positively and negatively valanced self-referent words, and participants were required to indicate whether they would like or dislike to be referred to as each word. In total, 40 words describing either extremely agreeable/positive characteristics (e.g. ‘cheerful’, ‘honest’, ‘optimistic’) or extremely disagreeable/negative characteristics (e.g. ‘domineering’, ‘untidy’, ‘hostile’) were presented individually in the centre of the screen for approximately 500 ms each. Positive and negative words were chosen to be comparable with regard to frequency, length and meaningfulness and were presented in a random order. Responses were made by pressing correspondingly labelled buttons on a keyboard. The main outcome of interest was the averaged reaction time for correct classifications, but accuracy was recorded to make sure participants were engaged with the task.</p>
                </sec>
                <sec id="section12-02698811221089032">
                  <title>Faces Dot Probe Task (FDOT)</title>
                  <p>In the FDOT, two faces (either an emotional (fearful or happy) or a neutral face) were shown at the top and at the bottom of the computer screen and then replaced by a pair of dots to which the participant had to respond by indicating whether the dots are vertically or horizontally aligned by pressing a labelled key on the keyboard. On half of the total 192 trials, the faces were presented very briefly and immediately switched to a muddled face mask. Attentional vigilance scores were calculated by subtracting the mean reaction time from trials when probes appeared in the same position as the emotional face (congruent trials) from trials when probes appeared in the opposite position to the emotional face (incongruent trials).</p>
                </sec>
                <sec id="section13-02698811221089032">
                  <title>Emotional Recall Task (EREC)</title>
                  <p>The EREC is a surprise free recall task during which participants were required to remember as many of the positively and negatively valanced self-referent words from the ECAT as they could in 4 min. The main outcomes of interest were the numbers of correctly and incorrectly recalled words.</p>
                </sec>
              </sec>
              <sec id="section14-02698811221089032">
                <title>Data analysis</title>
                <p>Analyses were carried out using SPSS for Windows (Version 25, IBM SPSS Statistics).</p>
                <p>Due to the non-normality of the raw data, we calculated change scores for VAS and POMS measures (baseline to post-testing). These were analysed by univariate analysis of variance (ANOVA) with COMT genotype (Met/Met vs Val/Val) and drug (placebo vs tolcapone) as between-subjects factors.</p>
                <p>Emotional processing measures were analysed using repeated-measures ANOVA with COMT genotype (Met/Met vs Val/Val) and drug (placebo vs tolcapone) as between-subjects factors and emotion/valence as the within-subjects factor. Additional within-subjects factors were included for the FDOT (mask condition) and EREC (recall accuracy). Huynh–Feldt correction was applied where data failed Mauchly’s Test of Sphericity. Planned post hoc comparisons were used to explore statistically significant interaction terms.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section15-02698811221089032">
              <title>Results</title>
              <p>The demographics of the final sample are shown in <xref rid="table1-02698811221089032" ref-type="table">Table 1</xref>. There were no robust effects of Val<sup>158</sup>Met genotype, inhibition or their interaction on any of the emotional processing measures (<xref rid="table2-02698811221089032" ref-type="table">Table 2</xref>). Thus, while there were main effects of emotion on accuracy, misclassifications and reaction time (<italic toggle="yes">F</italic>s &gt; 21; <italic toggle="yes">p</italic>s &lt; 4.7 × 10<sup>–37</sup>) during facial emotion recognition, there were no main or interactive effects of genotype or drug (<italic toggle="yes">F</italic>s &lt; 1.22; <italic toggle="yes">p</italic>s &gt; 0.31). There was a main effect of valence on reaction time (<italic toggle="yes">F</italic><sub>1,69</sub> = 32.0; <italic toggle="yes">p</italic> = 3.2 × 10<sup>–7</sup>) but not accuracy (<italic toggle="yes">F</italic><sub>1,69</sub> = 0.9; <italic toggle="yes">p</italic> = 0.35) during assessment of word valence but no other main or interactive effects (<italic toggle="yes">F</italic>s &lt; 0.61; <italic toggle="yes">p</italic>s &gt; 0.05); similar findings were obtained for their later recall (main effect of valence for correct recalls: <italic toggle="yes">F</italic><sub>1,69</sub> = 12.9; <italic toggle="yes">p</italic> = 0.001; main effect of valence for errors: <italic toggle="yes">F</italic><sub>1,69</sub> = 6.0; <italic toggle="yes">p</italic> = 0.017; other effects: <italic toggle="yes">F</italic>s &lt; 0.55; <italic toggle="yes">p</italic>s &gt; 0.47). Finally, other than a main effect of emotion (<italic toggle="yes">F</italic><sub>1,68</sub> = 11.6; <italic toggle="yes">p</italic> = 0.001), there were no other main or interactive effects on attentional vigilance towards happy or fearful faces (<italic toggle="yes">F</italic>s &lt; 1.61; <italic toggle="yes">p</italic>s &gt; 0.12).</p>
              <table-wrap position="float" id="table1-02698811221089032">
                <label>Table 1.</label>
                <caption>
                  <p>Demographics of participants.</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_02698811221089032-table1" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1">Met Placebo</th>
                        <th align="left" rowspan="1" colspan="1">Val Placebo</th>
                        <th align="left" rowspan="1" colspan="1">Met Tolcapone</th>
                        <th align="left" rowspan="1" colspan="1">Val Tolcapone</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>Number</bold>
                        </td>
                        <td rowspan="1" colspan="1">19</td>
                        <td rowspan="1" colspan="1">19</td>
                        <td rowspan="1" colspan="1">19</td>
                        <td rowspan="1" colspan="1">17</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>Age (years)</bold>
                        </td>
                        <td rowspan="1" colspan="1">23.3 ± 1.0</td>
                        <td rowspan="1" colspan="1">25.3 ± 1.3</td>
                        <td rowspan="1" colspan="1">24.8 ± 1.0</td>
                        <td rowspan="1" colspan="1">22.5 ± 1.2</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>NART predicted Full Scale IQ</bold>
                          <sup>
                            <xref rid="table-fn3-02698811221089032" ref-type="table-fn">a</xref>
                          </sup>
                        </td>
                        <td rowspan="1" colspan="1">117.1 ± 1.2</td>
                        <td rowspan="1" colspan="1">115.6 ± 1.8</td>
                        <td rowspan="1" colspan="1">115.9 ± 1.5</td>
                        <td rowspan="1" colspan="1">113.9 ± 1.7</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>Baseline State Anxiety</bold>
                          <sup>
                            <xref rid="table-fn4-02698811221089032" ref-type="table-fn">b</xref>
                          </sup>
                        </td>
                        <td rowspan="1" colspan="1">28.2 ± 1.2</td>
                        <td rowspan="1" colspan="1">28.1 ± 1.2</td>
                        <td rowspan="1" colspan="1">31.4 ± 1.8</td>
                        <td rowspan="1" colspan="1">30.2 ± 1.1</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">
                          <bold>Baseline Trait Anxiety</bold>
                          <sup>
                            <xref rid="table-fn4-02698811221089032" ref-type="table-fn">b</xref>
                          </sup>
                        </td>
                        <td rowspan="1" colspan="1">30.6 ± 1.7</td>
                        <td rowspan="1" colspan="1">32.1 ± 1.4</td>
                        <td rowspan="1" colspan="1">34.4 ± 2.1</td>
                        <td rowspan="1" colspan="1">32.1 ± 1.4</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn1-02698811221089032">
                    <p>NART: National Adult Reading Test.</p>
                  </fn>
                  <fn id="table-fn2-02698811221089032">
                    <p>Values are mean ± SEM.</p>
                  </fn>
                  <fn id="table-fn3-02698811221089032">
                    <label>a</label>
                    <p>Non-native speakers excluded.</p>
                  </fn>
                  <fn id="table-fn4-02698811221089032">
                    <label>b</label>
                    <p>Spielberger’s State-Trait Anxiety Inventory.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="table2-02698811221089032">
                <label>Table 2.</label>
                <caption>
                  <p>Behavioural measures of emotional processing measured using the Emotional Test Battery (ETB).</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_02698811221089032-table2" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1"/>
                        <th align="left" rowspan="1" colspan="1">Val Placebo</th>
                        <th align="left" rowspan="1" colspan="1">Met Placebo</th>
                        <th align="left" rowspan="1" colspan="1">Val Tolcapone</th>
                        <th align="left" rowspan="1" colspan="1">Met Tolcapone</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="5" rowspan="1">
                          <bold>Facial</bold>
                          <bold>Expression</bold>
                          <bold>Recognition</bold>
                          <bold>Task (FERT)</bold>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1"> <bold>Accuracy (%)</bold></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Anger</bold></td>
                        <td rowspan="1" colspan="1">46.3 ± 2.3</td>
                        <td rowspan="1" colspan="1">50.0 ± 2.1</td>
                        <td rowspan="1" colspan="1">51.9 ± 3.0</td>
                        <td rowspan="1" colspan="1">46.7 ± 3.2</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Disgust</bold></td>
                        <td rowspan="1" colspan="1">42.5 ± 3.3</td>
                        <td rowspan="1" colspan="1">47.9 ± 3.0</td>
                        <td rowspan="1" colspan="1">44.2 ± 4.1</td>
                        <td rowspan="1" colspan="1">47.0 ± 4.0</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Fear</bold></td>
                        <td rowspan="1" colspan="1">43.3 ± 3.4</td>
                        <td rowspan="1" colspan="1">44.6 ± 4.1</td>
                        <td rowspan="1" colspan="1">45.2 ± 3.5</td>
                        <td rowspan="1" colspan="1">48.8 ± 3.6</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Happy</bold></td>
                        <td rowspan="1" colspan="1">68.5 ± 2.6</td>
                        <td rowspan="1" colspan="1">66.9 ± 2.0</td>
                        <td rowspan="1" colspan="1">63.1 ± 1.8</td>
                        <td rowspan="1" colspan="1">65.0 ± 3.1</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Sad</bold></td>
                        <td rowspan="1" colspan="1">44.6 ± 2.6</td>
                        <td rowspan="1" colspan="1">49.6 ± 2.3</td>
                        <td rowspan="1" colspan="1">50.0 ± 4.0</td>
                        <td rowspan="1" colspan="1">50.8 ± 3.6</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Surprise</bold></td>
                        <td rowspan="1" colspan="1">57.6 ± 2.0</td>
                        <td rowspan="1" colspan="1">55.7 ± 2.8</td>
                        <td rowspan="1" colspan="1">58.0 ± 2.1</td>
                        <td rowspan="1" colspan="1">54.5 ± 2.7</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Neutral</bold></td>
                        <td rowspan="1" colspan="1">68.9 ± 4.5</td>
                        <td rowspan="1" colspan="1">69.4 ± 4.3</td>
                        <td rowspan="1" colspan="1">71.9 ± 3.9</td>
                        <td rowspan="1" colspan="1">71.1 ± 3.8</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1"> <bold>Misclassifications (%)</bold></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Anger</bold></td>
                        <td rowspan="1" colspan="1">14.5 ± 2.2</td>
                        <td rowspan="1" colspan="1">14.1 ± 1.7</td>
                        <td rowspan="1" colspan="1">13.1 ± 1.6</td>
                        <td rowspan="1" colspan="1">14.2 ± 1.2</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Disgust</bold></td>
                        <td rowspan="1" colspan="1">10.4 ± 2.0</td>
                        <td rowspan="1" colspan="1">7.3 ± 1.5</td>
                        <td rowspan="1" colspan="1">7.5 ± 1.5</td>
                        <td rowspan="1" colspan="1">9.0 ± 1.4</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Fear</bold></td>
                        <td rowspan="1" colspan="1">8.0 ± 1.3</td>
                        <td rowspan="1" colspan="1">8.2 ± 1.4</td>
                        <td rowspan="1" colspan="1">7.1 ± 1.1</td>
                        <td rowspan="1" colspan="1">7.1 ± 0.9</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Happy</bold></td>
                        <td rowspan="1" colspan="1">2.2 ± 0.6</td>
                        <td rowspan="1" colspan="1">3.4 ± 0.9</td>
                        <td rowspan="1" colspan="1">2.8 ± 0.6</td>
                        <td rowspan="1" colspan="1">5.5 ± 2.1</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Sad</bold></td>
                        <td rowspan="1" colspan="1">8.79 ± 1.4</td>
                        <td rowspan="1" colspan="1">9.94 ± 1.9</td>
                        <td rowspan="1" colspan="1">8.31 ± 2.2</td>
                        <td rowspan="1" colspan="1">8.89 ± 1.7</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Surprise</bold></td>
                        <td rowspan="1" colspan="1">10.31 ± 1.4</td>
                        <td rowspan="1" colspan="1">12.83 ± 1.8</td>
                        <td rowspan="1" colspan="1">11.00 ± 2.0</td>
                        <td rowspan="1" colspan="1">11.94 ± 1.6</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Neutral</bold></td>
                        <td rowspan="1" colspan="1">63.26 ± 4.1</td>
                        <td rowspan="1" colspan="1">67.33 ± 4.7</td>
                        <td rowspan="1" colspan="1">67.75 ± 4.6</td>
                        <td rowspan="1" colspan="1">64.89 ± 3.3</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1"> <bold>Reaction time</bold> (<bold>ms</bold>)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Anger</bold></td>
                        <td rowspan="1" colspan="1">1798 ± 91</td>
                        <td rowspan="1" colspan="1">1820 ± 107</td>
                        <td rowspan="1" colspan="1">1795 ± 81</td>
                        <td rowspan="1" colspan="1">1776 ± 84</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Disgust</bold></td>
                        <td rowspan="1" colspan="1">1794 ± 120</td>
                        <td rowspan="1" colspan="1">1897 ± 113</td>
                        <td rowspan="1" colspan="1">1800 ± 67</td>
                        <td rowspan="1" colspan="1">2009 ± 113</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Fear</bold></td>
                        <td rowspan="1" colspan="1">2122 ± 75</td>
                        <td rowspan="1" colspan="1">2167 ± 117</td>
                        <td rowspan="1" colspan="1">2104 ± 144</td>
                        <td rowspan="1" colspan="1">2104 ± 107</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Happy</bold></td>
                        <td rowspan="1" colspan="1">1653 ± 64</td>
                        <td rowspan="1" colspan="1">1603 ± 53</td>
                        <td rowspan="1" colspan="1">1598 ± 51</td>
                        <td rowspan="1" colspan="1">1604 ± 74</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Sad</bold></td>
                        <td rowspan="1" colspan="1">1858 ± 71</td>
                        <td rowspan="1" colspan="1">1973 ± 98</td>
                        <td rowspan="1" colspan="1">1907 ± 87</td>
                        <td rowspan="1" colspan="1">1866 ± 91</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Surprise</bold></td>
                        <td rowspan="1" colspan="1">1907 ± 122</td>
                        <td rowspan="1" colspan="1">1822 ± 95</td>
                        <td rowspan="1" colspan="1">1817 ± 72</td>
                        <td rowspan="1" colspan="1">1951 ± 98</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Neutral</bold></td>
                        <td rowspan="1" colspan="1">1748 ± 126</td>
                        <td rowspan="1" colspan="1">1725 ± 149</td>
                        <td rowspan="1" colspan="1">1655 ± 116</td>
                        <td rowspan="1" colspan="1">1520 ± 92</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">
                          <bold>Emotional</bold>
                          <bold>Categorisation</bold>
                          <bold>Task (ECAT)</bold>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1"> <bold>Reaction time (ms)</bold></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Positive</bold></td>
                        <td rowspan="1" colspan="1">1047 ± 64</td>
                        <td rowspan="1" colspan="1">1104 ± 50</td>
                        <td rowspan="1" colspan="1">1132 ± 42</td>
                        <td rowspan="1" colspan="1">1073 ± 51</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Negative</bold></td>
                        <td rowspan="1" colspan="1">1158 ± 59</td>
                        <td rowspan="1" colspan="1">1122 ± 37</td>
                        <td rowspan="1" colspan="1">1224 ± 54</td>
                        <td rowspan="1" colspan="1">1163 ± 58</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">
                          <bold>Faces</bold>
                          <bold>Dot</bold>
                          <bold>Probe</bold>
                          <bold>Task (FDOT)</bold>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1"> <bold>Vigilance bias score (ms)</bold></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Unmasked positive</bold></td>
                        <td rowspan="1" colspan="1">11 ± 9</td>
                        <td rowspan="1" colspan="1">−18 ± 8</td>
                        <td rowspan="1" colspan="1">−4 ± 9</td>
                        <td rowspan="1" colspan="1">−11 ± 7</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Unmasked negative</bold></td>
                        <td rowspan="1" colspan="1">6 ± 9</td>
                        <td rowspan="1" colspan="1">−4 ± 9</td>
                        <td rowspan="1" colspan="1">−1 ± 7</td>
                        <td rowspan="1" colspan="1">20 ± 11</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Masked positive</bold></td>
                        <td rowspan="1" colspan="1">−10 ± 10</td>
                        <td rowspan="1" colspan="1">−4 ± 11</td>
                        <td rowspan="1" colspan="1">−15 ± 7</td>
                        <td rowspan="1" colspan="1">−24 ± 10</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Masked negative</bold></td>
                        <td rowspan="1" colspan="1">10 ± 11</td>
                        <td rowspan="1" colspan="1">6 ± 10</td>
                        <td rowspan="1" colspan="1">9 ± 9</td>
                        <td rowspan="1" colspan="1">10 ± 7</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">
                          <bold>Emotional</bold>
                          <bold>Recall</bold>
                          <bold>Task (EREC)</bold>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1"> <bold>Hits (n correct)</bold></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Positive</bold></td>
                        <td rowspan="1" colspan="1">4.0 ± 0.5</td>
                        <td rowspan="1" colspan="1">4.9 ± 0.6</td>
                        <td rowspan="1" colspan="1">4.0 ± 0.6</td>
                        <td rowspan="1" colspan="1">4.8 ± 0.5</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Negative</bold></td>
                        <td rowspan="1" colspan="1">3.1 ± 0.5</td>
                        <td rowspan="1" colspan="1">3.9 ± 0.4</td>
                        <td rowspan="1" colspan="1">3.5 ± 0.5</td>
                        <td rowspan="1" colspan="1">3.6 ± 0.5</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1"> <bold>Intrusions (n wrong)</bold></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Positive</bold></td>
                        <td rowspan="1" colspan="1">2.2 ± 0.5</td>
                        <td rowspan="1" colspan="1">1.8 ± 0.4</td>
                        <td rowspan="1" colspan="1">1.7 ± 0.3</td>
                        <td rowspan="1" colspan="1">2.1 ± 0.4</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">  <bold>Negative</bold></td>
                        <td rowspan="1" colspan="1">1.7 ± 0.6</td>
                        <td rowspan="1" colspan="1">0.9 ± 0.3</td>
                        <td rowspan="1" colspan="1">1.3 ± 0.3</td>
                        <td rowspan="1" colspan="1">1.2 ± 0.6</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn5-02698811221089032">
                    <p>Values are mean ± SEM.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Comparing pre- and post-testing timepoints, there were no main or interactive effects on change scores for subjective mood VAS ratings (i.e. happiness, sadness or anxiety: <italic toggle="yes">F</italic>s &lt; 0.43; <italic toggle="yes">p</italic>s &gt; 0.51) or total mood disturbance (POMS) (<italic toggle="yes">F</italic>s &lt; 0.39; <italic toggle="yes">p</italic>s &gt; 0.54; <xref rid="fig1-02698811221089032" ref-type="fig">Figure 1</xref>). There was a main effect of drug on VAS drowsiness (<italic toggle="yes">F</italic><sub>1,69</sub> = 4.2; <italic toggle="yes">p</italic> = 0.044; change in drowsiness greater in tolcapone than placebo) in the absence of other main or interactive effects (<italic toggle="yes">F</italic>s &lt; 3.0; <italic toggle="yes">p</italic>s &gt; 0.089; <xref rid="fig1-02698811221089032" ref-type="fig">Figure 1</xref>). However, there were no effects on VAS alertness ratings (<italic toggle="yes">F</italic>s &lt; 1.4; <italic toggle="yes">p</italic>s &gt; 0.24; <xref rid="fig1-02698811221089032" ref-type="fig">Figure 1</xref>). Finally, there was a drug × genotype interaction for VAS nausea ratings (<italic toggle="yes">F</italic><sub>1,69</sub> = 4.4; <italic toggle="yes">p</italic> = 0.039) in the absence of other main effects (<italic toggle="yes">F</italic>s &lt; 1.1; <italic toggle="yes">p</italic>s &gt; 0.31), due to a genotype difference (Val &gt; Met; <italic toggle="yes">p</italic> = 0.03) in the placebo group that was not observed in the tolcapone group (<italic toggle="yes">p</italic> = 0.44).</p>
              <fig position="float" id="fig1-02698811221089032">
                <label>Figure 1.</label>
                <caption>
                  <p>Changes in subjective ratings in the different genotype and drug groups. The change scores from pre–post drug timepoints are shown broken down by group. Boxes indicate the median, 25th and 75th percentile values, with the whiskers indicating the maximum and minimum values. Only self-rated drowsiness and nausea differed between groups (see text for details).</p>
                  <p>POMS TMD: Profile of Mood States Total Mood Disturbance; VAS: visual analogue scales; Plc: Placebo; Tol: Tolcapone.</p>
                </caption>
                <graphic xlink:href="10.1177_02698811221089032-fig1" position="float"/>
              </fig>
            </sec>
            <sec sec-type="discussion" id="section16-02698811221089032">
              <title>Discussion</title>
              <p>We found no effect of either COMT inhibition or COMT Val<sup>158</sup>Met genotype on performance on an emotional test battery or any effects on subjective mood ratings. Thus, our findings suggest that, at least in healthy men, COMT does not influence behavioural measures of emotional processing. To our knowledge, ours is the first study to examine the effect on COMT genotype on multiple aspects of emotional processing and mood within a single cohort of human volunteers as well as the first to assess the impact of acute COMT inhibition on these processes. Given the similarities in experimental design and study population, the current data suggest that our previous finding of a positive effect of tolcapone on subjective happiness ratings represents a false positive (<xref rid="bibr16-02698811221089032" ref-type="bibr">Farrell et al., 2012</xref>), consistent with a lack of effect of COMT genotype on subjective mood ratings reported elsewhere (<xref rid="bibr21-02698811221089032" ref-type="bibr">Gibbs et al., 2014</xref>).</p>
              <p>Detection of facial emotions is the area of emotional behaviour that is best studied with respect to COMT genotype, although a variety of different experimental approaches have been employed. Our findings agree with most earlier studies showing no overall effect of COMT genotype on facial emotion detection (<xref rid="bibr5-02698811221089032" ref-type="bibr">Carrà et al., 2017</xref>; <xref rid="bibr8-02698811221089032" ref-type="bibr">Defrancesco et al., 2011</xref>; <xref rid="bibr34-02698811221089032" ref-type="bibr">Kempton et al., 2009</xref>; <xref rid="bibr52-02698811221089032" ref-type="bibr">Soeiro-de-Souza et al., 2012</xref>; <xref rid="bibr56-02698811221089032" ref-type="bibr">Tamm et al., 2016</xref>). We cannot rule out more subtle effects of COMT on detection of specific types of emotional information. However, it is notable that where more subtle differences have been found, results are inconsistent. For example, while some studies found genotype effects that were specific to negative emotions (<xref rid="bibr38-02698811221089032" ref-type="bibr">Lischke et al., 2019</xref>; <xref rid="bibr64-02698811221089032" ref-type="bibr">Weiss et al., 2007</xref>), other studies report altered detection of neutral, but not emotional, facial expressions associated with COMT (<xref rid="bibr14-02698811221089032" ref-type="bibr">Erkoreka et al., 2020</xref>; <xref rid="bibr23-02698811221089032" ref-type="bibr">Gohier et al., 2014</xref>).</p>
              <p>Our negative behavioural findings are of interest in the context of the better-studied relationship between COMT genotype and brain activation during emotional processing. Thus, although there are some conflicting reports (<xref rid="bibr3-02698811221089032" ref-type="bibr">Bishop et al., 2006</xref>; <xref rid="bibr10-02698811221089032" ref-type="bibr">Domschke et al., 2012</xref>), most studies (including by meta-analysis) suggest that the Met allele is associated with greater limbic activation during emotional processing (<xref rid="bibr12-02698811221089032" ref-type="bibr">Drabant et al., 2006</xref>; <xref rid="bibr43-02698811221089032" ref-type="bibr">Mier et al., 2010</xref>). There is also some evidence that COMT genotype influences patterns of functional connectivity during emotional processing (<xref rid="bibr45-02698811221089032" ref-type="bibr">Opmeer et al., 2013</xref>; <xref rid="bibr63-02698811221089032" ref-type="bibr">Vai et al., 2017</xref>; but see <xref rid="bibr55-02698811221089032" ref-type="bibr">Surguladze et al., 2012</xref>). Notably, this disconnect between neural measures and behavioural effects has been observed within subjects, both in the specific case of COMT genotype (<xref rid="bibr34-02698811221089032" ref-type="bibr">Kempton et al., 2009</xref>) and after other manipulations of dopamine function (<xref rid="bibr40-02698811221089032" ref-type="bibr">Martens et al., 2021</xref>). It is possible that that measurements of quantitative biological traits, such as BOLD response, are more sensitive to the subtle effects of genetic variation than studies looking at overt behaviour (<xref rid="bibr42-02698811221089032" ref-type="bibr">Meyer-Lindenberg and Weinberger, 2006</xref>). Alternatively, in the case of genetically encoded differences such as COMT Val<sup>158</sup>Met that presumably affect enzyme activity throughout development (<xref rid="bibr60-02698811221089032" ref-type="bibr">Tunbridge et al., 2007</xref>), it is possible that differences observed at the neural level represent compensatory changes in the precise circuitry used to achieve a given behavioural outcome. It may be that such subtle differences in ‘wiring’ are insufficient to lead to any observable behavioural differences in healthy controls under baseline conditions. It is therefore notable that there is some evidence, albeit inconsistent, for associations between COMT genotype and emotion-related behaviours that are modulated by environmental adversity (<xref rid="bibr1-02698811221089032" ref-type="bibr">Asselmann et al., 2018</xref>; <xref rid="bibr15-02698811221089032" ref-type="bibr">Evans et al., 2009</xref>; <xref rid="bibr39-02698811221089032" ref-type="bibr">Lovallo et al., 2017</xref>). Given the difficulty in disentangling such effects in epidemiological studies, it will be of interest to investigate the impact of stressors and other challenges on the relationships between COMT activity and emotional processing under controlled laboratory conditions.</p>
              <p>Taken together, our data suggest that variation in COMT activity, whether genetic or pharmacological in origin, has no demonstrable effect on mood and emotional processing in healthy men under baseline conditions. Nevertheless, given the design and demographics of this study, further research is required to investigate the extent to which our findings generalise to other populations, to establish how COMT-related differences in neural processing relate to emotional behaviours and to assess whether prolonged COMT inhibition affects emotional processing. Our findings do not have immediate therapeutic relevance, since the licenced COMT inhibitors are either not brain-penetrant or are limited by hepatotoxicity. However, our results suggest that the novel, brain-penetrant COMT inhibitors under development for cognitive dysfunction (<xref rid="bibr4-02698811221089032" ref-type="bibr">Byers et al., 2020</xref>) are unlikely to have major off-target effects on mood and related behaviours, at least when administered acutely.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>This study was supported by the National Institute for Health Research Oxford Health Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.</p>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement">
                <p><bold>Declaration of conflicting interests:</bold> The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: E.M.T. is in receipt of an unrestricted educational grant from J&amp;J Innovations and funding from Biogen and Boehringer Ingelheim via the Psychiatry Consortium of the Medicines Discovery Catapult for projects unrelated to the research presented here. E.M.T. also provides consultancy for Ono Pharmaceuticals and serves on the Scientific Advisory Board for Boehringer Ingelheim. Since the initial submission of this manuscript, E.M.T. has become a full-time employee of Boehringer Ingelheim. None of these industrial partners had any involvement in the conduct, the analysis or reporting the research presented here. C.J.H. has received consultancy fees from P1vital Ltd., Janssen Pharmaceuticals, Sage Therapeutics, Pfizer, Zogenix, Compass Pathways and Lundbeck. Moreover, C.J.H. holds grant income from Zogenix, UCB Pharma, Janssen Pharmaceuticals and a collaborative research project with Pfizer. P.J.H. is an expert witness in patent litigation cases unrelated to the work presented here.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by a MRC Project Grant (MR/K013092/1) awarded to P.J.H., E.M.T. and C.J.H. E.M.T., M.A.G.M., P.J.H. and C.J.H. are supported by the NIHR Oxford Health Biomedical Research Centre.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> Marieke AG Martens <inline-graphic xlink:href="10.1177_02698811221089032-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0003-0108-1327" ext-link-type="uri">https://orcid.org/0000-0003-0108-1327</ext-link></p>
                <p>Paul J Harrison <inline-graphic xlink:href="10.1177_02698811221089032-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-6719-1126" ext-link-type="uri">https://orcid.org/0000-0002-6719-1126</ext-link></p>
                <p>Elizabeth M Tunbridge <inline-graphic xlink:href="10.1177_02698811221089032-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-2966-2281" ext-link-type="uri">https://orcid.org/0000-0002-2966-2281</ext-link></p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asselmann</surname><given-names>E</given-names></name><name><surname>Hertel</surname><given-names>J</given-names></name><name><surname>Beesdo-Baum</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Interplay between COMT Val158Met, childhood adversities and sex in predicting panic pathology: Findings from a general population sample</article-title>. <source>Journal of Affective Disorders</source><volume>234</volume>: <fpage>290</fpage>–<lpage>296</lpage>.<pub-id pub-id-type="pmid">29574383</pub-id></mixed-citation>
              </ref>
              <ref id="bibr2-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkus</surname><given-names>C</given-names></name><name><surname>Korn</surname><given-names>C</given-names></name><name><surname>Stumpenhorst</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Genotype-dependent effects of COMT inhibition on cognitive function in a highly specific, novel mouse model of altered COMT activity</article-title>. <source>Neuropsychopharmacology</source><volume>41</volume>(<issue>13</issue>): <fpage>3060</fpage>–<lpage>3069</lpage>.<pub-id pub-id-type="pmid">27388330</pub-id></mixed-citation>
              </ref>
              <ref id="bibr3-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>SJ</given-names></name><name><surname>Cohen</surname><given-names>JD</given-names></name><name><surname>Fossella</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>2006</year>) <article-title>COMT genotype influences prefrontal response to emotional distraction</article-title>. <source>Cognitive, Affective, &amp; Behavioral Neuroscience</source><volume>6</volume>(<issue>1</issue>): <fpage>62</fpage>–<lpage>70</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr4-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byers</surname><given-names>S</given-names></name><name><surname>Buchler</surname><given-names>IP</given-names></name><name><surname>DePasquale</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility</article-title>. <source>Psychopharmacology</source><volume>237</volume>(<issue>9</issue>): <fpage>2695</fpage>–<lpage>2707</lpage>.<pub-id pub-id-type="pmid">32474681</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrà</surname><given-names>G</given-names></name><name><surname>Nicolini</surname><given-names>G</given-names></name><name><surname>Lax</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. (<year>2017</year>) <article-title>Facial emotion recognition in schizophrenia: An exploratory study on the role of comorbid alcohol and substance use disorders and COMT Val158Met</article-title>. <source>Human Psychopharmacology: Clinical and Experimental</source><volume>32</volume>(<issue>6</issue>): e2630.</mixed-citation>
              </ref>
              <ref id="bibr6-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceravolo</surname><given-names>R</given-names></name><name><surname>Piccini</surname><given-names>P</given-names></name><name><surname>Bailey</surname><given-names>DL</given-names></name></person-group>, <etal>et al</etal>. (<year>2002</year>) <article-title>18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease</article-title>. <source>Synapse</source><volume>43</volume>(<issue>3</issue>): <fpage>201</fpage>–<lpage>207</lpage>.<pub-id pub-id-type="pmid">11793426</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBrosse</surname><given-names>AC</given-names></name><name><surname>Wheeler</surname><given-names>AM</given-names></name><name><surname>Barrow</surname><given-names>JC</given-names></name></person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Inhibition of catechol-O-methyltransferase does not alter effort-related choice behavior in a fixed ratio/concurrent chow task in male mice</article-title>. <source>Frontiers in Behavioral Neuroscience</source><volume>14</volume>: <fpage>73</fpage>.<pub-id pub-id-type="pmid">32508604</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defrancesco</surname><given-names>M</given-names></name><name><surname>Niederstätter</surname><given-names>H</given-names></name><name><surname>Parson</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>. (<year>2011</year>) <article-title>Influence of serotonin transporter genotype and catechol-O-methyltransferase Val158Met polymorphism on recognition of emotional faces</article-title>. <source>Journal of the International Neuropsychological Society</source><volume>17</volume>(<issue>6</issue>): <fpage>1014</fpage>–<lpage>1020</lpage>.<pub-id pub-id-type="pmid">22013977</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingemanse</surname><given-names>J</given-names></name><name><surname>Jorga</surname><given-names>KM</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. (<year>1995</year>) <article-title>Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans</article-title>. <source>Clinical Pharmacology &amp; Therapeutics</source><volume>57</volume>(<issue>5</issue>): <fpage>508</fpage>–<lpage>517</lpage>.<pub-id pub-id-type="pmid">7768073</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domschke</surname><given-names>K</given-names></name><name><surname>Baune</surname><given-names>BT</given-names></name><name><surname>Havlik</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>Catechol-O-methyltransferase gene variation: Impact on amygdala response to aversive stimuli</article-title>. <source>NeuroImage</source><volume>60</volume>(<issue>4</issue>): <fpage>2222</fpage>–<lpage>2229</lpage>.<pub-id pub-id-type="pmid">22387174</pub-id></mixed-citation>
              </ref>
              <ref id="bibr11-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domschke</surname><given-names>K</given-names></name><name><surname>Freitag</surname><given-names>CM</given-names></name><name><surname>Kuhlenbäumer</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. (<year>2004</year>) <article-title>Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women</article-title>. <source>International Journal of Neuropsychopharmacology</source><volume>7</volume>(<issue>2</issue>): <fpage>183</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">15009906</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drabant</surname><given-names>EM</given-names></name><name><surname>Hariri</surname><given-names>AR</given-names></name><name><surname>Meyer-Lindenberg</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>. (<year>2006</year>) <article-title>Catechol O-methyltransferase Val158Met genotype and neural mechanisms related to affective arousal and regulation</article-title>. <source>Archives of General Psychiatry</source><volume>63</volume>: <fpage>11</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr13-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunlop</surname><given-names>BW</given-names></name><name><surname>Nemeroff</surname><given-names>CB</given-names></name></person-group> (<year>2007</year>) <article-title>The role of dopamine in the pathophysiology of depression</article-title>. <source>Archives of General Psychiatry</source>
<volume>64</volume>(<issue>3</issue>): <fpage>327</fpage>–<lpage>337</lpage>.<pub-id pub-id-type="pmid">17339521</pub-id></mixed-citation>
              </ref>
              <ref id="bibr14-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erkoreka</surname><given-names>L</given-names></name><name><surname>Zamalloa</surname><given-names>I</given-names></name><name><surname>Rodriguez</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2020</year>) <article-title>Genetic modulation of facial emotion recognition in borderline personality disorder</article-title>. <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source><volume>99</volume>: <fpage>109816</fpage>.<pub-id pub-id-type="pmid">31738966</pub-id></mixed-citation>
              </ref>
              <ref id="bibr15-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Heron</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>2009</year>) <article-title>Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype</article-title>. <source>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics B</source><volume>150</volume>: <fpage>2209</fpage>–<lpage>2218</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr16-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>SM</given-names></name><name><surname>Tunbridge</surname><given-names>EM</given-names></name><name><surname>Braeutigam</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>COMT Val158Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition</article-title>. <source>Biological Psychiatry</source><volume>71</volume>(<issue>6</issue>): <fpage>538</fpage>–<lpage>544</lpage>.<pub-id pub-id-type="pmid">22364739</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Rosenbaum</surname><given-names>JF</given-names></name><name><surname>Kolsky</surname><given-names>AR</given-names></name></person-group>, <etal>et al</etal>. (<year>1999</year>) <article-title>Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder</article-title>. <source>Journal of Clinical Psychopharmacology</source><volume>19</volume>(<issue>4</issue>): <fpage>329</fpage>–<lpage>335</lpage>.<pub-id pub-id-type="pmid">10440460</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figee</surname><given-names>M</given-names></name><name><surname>Pattij</surname><given-names>T</given-names></name><name><surname>Willuhn</surname><given-names>I</given-names></name></person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Compulsivity in obsessive–compulsive disorder and addictions</article-title>. <source>European Neuropsychopharmacology</source><volume>26</volume>(<issue>5</issue>): <fpage>856</fpage>–<lpage>868</lpage>.<pub-id pub-id-type="pmid">26774279</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparini</surname><given-names>M</given-names></name><name><surname>Fabrizio</surname><given-names>E</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>. (<year>1997</year>) <article-title>Cognitive improvement during tolcapone treatment in Parkinson’s disease</article-title>. <source>Journal of Neural Transmission</source><volume>104</volume>(<issue>8–9</issue>): <fpage>887</fpage>–<lpage>894</lpage>.<pub-id pub-id-type="pmid">9451720</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giakoumaki</surname><given-names>SG</given-names></name><name><surname>Roussos</surname><given-names>P</given-names></name><name><surname>Bitsios</surname><given-names>P</given-names></name></person-group> (<year>2008</year>) <article-title>Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism</article-title>. <source>Neuropsychopharmacology</source>
<volume>33</volume>(<issue>13</issue>): <fpage>3058</fpage>–<lpage>3068</lpage>.<pub-id pub-id-type="pmid">18536698</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>AA</given-names></name><name><surname>Bautista</surname><given-names>CE</given-names></name><name><surname>Mowlem</surname><given-names>FD</given-names></name></person-group>, <etal>et al</etal>. (<year>2014</year>) <article-title>Catechol-O-methyltransferase val158met genotype determines effect of reboxetine on emotional memory in healthy male volunteers</article-title>. <source>Journal of Psychiatry &amp; Neuroscience: JPN</source><volume>39</volume>(<issue>3</issue>): E24–E31.</mixed-citation>
              </ref>
              <ref id="bibr22-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gogos</surname><given-names>JA</given-names></name><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Luine</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>. (<year>1998</year>) <article-title>Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior</article-title>. <source>Proceedings of the National Academy of Sciences</source><volume>95</volume>(<issue>17</issue>): <fpage>9991</fpage>–<lpage>9996</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr23-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gohier</surname><given-names>B</given-names></name><name><surname>Senior</surname><given-names>C</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>2014</year>) <article-title>Genetic modulation of the response bias towards facial displays of anger and happiness</article-title>. <source>European Psychiatry</source><volume>29</volume>(<issue>4</issue>): <fpage>197</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="pmid">23769682</pub-id></mixed-citation>
              </ref>
              <ref id="bibr24-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group> (<year>2000</year>) <article-title>D1 receptors in prefrontal cells and circuits</article-title>. <source>Brain Research Reviews</source>
<volume>31</volume>(<issue>2–3</issue>): <fpage>295</fpage>–<lpage>301</lpage>.<pub-id pub-id-type="pmid">10719156</pub-id></mixed-citation>
              </ref>
              <ref id="bibr25-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name><name><surname>Castner</surname><given-names>SA</given-names></name><name><surname>Svensson</surname><given-names>TH</given-names></name></person-group>, <etal>et al</etal>. (<year>2004</year>) <article-title>Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction</article-title>. <source>Psychopharmacology</source><volume>174</volume>(<issue>1</issue>): <fpage>3</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">15118803</pub-id></mixed-citation>
              </ref>
              <ref id="bibr26-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2013</year>) <article-title>Genetic variations in COMT and DRD2 modulate attentional bias for affective facial expressions</article-title>. <source>PLoS ONE</source><volume>8</volume>(<issue>12</issue>): e81446.</mixed-citation>
              </ref>
              <ref id="bibr27-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon-Fennell</surname><given-names>A</given-names></name><name><surname>Stuber</surname><given-names>GD</given-names></name></person-group> (<year>2021</year>) <article-title>Illuminating subcortical GABAergic and glutamatergic circuits for reward and aversion</article-title>. <source>Neuropharmacology</source>
<volume>198</volume>: <fpage>108725</fpage>.<pub-id pub-id-type="pmid">34375625</pub-id></mixed-citation>
              </ref>
              <ref id="bibr28-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>AA</given-names></name><name><surname>Rosenkranz</surname><given-names>JA</given-names></name></person-group> (<year>2002</year>) <article-title>Regulation of conditioned responses of basolateral amygdala neurons</article-title>. <source>Physiology &amp; Behavior</source>
<volume>77</volume>(<issue>4</issue>): <fpage>489</fpage>–<lpage>493</lpage>.<pub-id pub-id-type="pmid">12526988</pub-id></mixed-citation>
              </ref>
              <ref id="bibr29-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmer</surname><given-names>CJ</given-names></name><name><surname>de Bodinat</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>GR</given-names></name></person-group>, <etal>et al</etal>. (<year>2011</year>) <article-title>Agomelatine facilitates positive versus negative affective processing in healthy volunteer models</article-title>. <source>Journal of Psychopharmacology</source><volume>25</volume>(<issue>9</issue>): <fpage>1159</fpage>–<lpage>1167</lpage>.<pub-id pub-id-type="pmid">20660010</pub-id></mixed-citation>
              </ref>
              <ref id="bibr30-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmer</surname><given-names>CJ</given-names></name><name><surname>O’Sullivan</surname><given-names>U</given-names></name><name><surname>Favaron</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. (<year>2009</year>) <article-title>Effect of acute antidepressant administration on negative affective bias in depressed patients</article-title>. <source>American Journal of Psychiatry</source><volume>166</volume>(<issue>10</issue>): <fpage>1178</fpage>–<lpage>1184</lpage>.<pub-id pub-id-type="pmid">19755572</pub-id></mixed-citation>
              </ref>
              <ref id="bibr31-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmer</surname><given-names>CJ</given-names></name><name><surname>Shelley</surname><given-names>NC</given-names></name><name><surname>Cowen</surname><given-names>PJ</given-names></name></person-group>, <etal>et al</etal>. (<year>2004</year>) <article-title>Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition</article-title>. <source>American Journal of Psychiatry</source><volume>161</volume>(<issue>7</issue>): <fpage>1256</fpage>–<lpage>1263</lpage>.<pub-id pub-id-type="pmid">15229059</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>PJ</given-names></name><name><surname>Tunbridge</surname><given-names>EM</given-names></name></person-group> (<year>2008</year>) <article-title>Catechol-O-methyltransferase (COMT): A gene contributing to sex differences in brain function and to sexual dimorphism in the predisposition to psychiatric disorders</article-title>. <source>Neuropsychopharmacology</source>
<volume>33</volume>(<issue>13</issue>): <fpage>3037</fpage>–<lpage>3045</lpage>.<pub-id pub-id-type="pmid">17805313</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karreman</surname><given-names>M</given-names></name><name><surname>Moghaddam</surname><given-names>B</given-names></name></person-group> (<year>1996</year>) <article-title>The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: An effect mediated by ventral tegmental area</article-title>. <source>Journal of Neurochemistry</source>
<volume>66</volume>(<issue>2</issue>): <fpage>589</fpage>–<lpage>598</lpage>.<pub-id pub-id-type="pmid">8592128</pub-id></mixed-citation>
              </ref>
              <ref id="bibr34-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempton</surname><given-names>MJ</given-names></name><name><surname>Haldane</surname><given-names>M</given-names></name><name><surname>Jogia</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>2009</year>) <article-title>The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: A fMRI study</article-title>. <source>The International Journal of Neuropsychopharmacology</source><volume>12</volume>(<issue>3</issue>): <fpage>371</fpage>.<pub-id pub-id-type="pmid">18796186</pub-id></mixed-citation>
              </ref>
              <ref id="bibr35-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolassa</surname><given-names>I-T</given-names></name><name><surname>Kolassa</surname><given-names>S</given-names></name><name><surname>Ertl</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>. (<year>2010</year>) <article-title>The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-O-methyltransferase Val158Met polymorphism</article-title>. <source>Biological Psychiatry</source><volume>67</volume>(<issue>4</issue>): <fpage>304</fpage>–<lpage>308</lpage>.<pub-id pub-id-type="pmid">19944409</pub-id></mixed-citation>
              </ref>
              <ref id="bibr36-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korn</surname><given-names>C</given-names></name><name><surname>Akam</surname><given-names>T</given-names></name><name><surname>Jensen</surname><given-names>KH</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Distinct roles for dopamine clearance mechanisms in regulating behavioral flexibility</article-title>. <source>Molecular Psychiatry</source><volume>26</volume>: <fpage>7188</fpage>–<lpage>7199</lpage>.<pub-id pub-id-type="pmid">34193974</pub-id></mixed-citation>
              </ref>
              <ref id="bibr37-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laatikainen</surname><given-names>LM</given-names></name><name><surname>Sharp</surname><given-names>T</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name></person-group>, <etal>et al</etal>. (<year>2013</year>) <article-title>Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions</article-title>. <source>PLoS ONE</source><volume>8</volume>(<issue>4</issue>): e61839.</mixed-citation>
              </ref>
              <ref id="bibr38-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lischke</surname><given-names>A</given-names></name><name><surname>Pahnke</surname><given-names>R</given-names></name><name><surname>König</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>2019</year>) <article-title>COMTVal158Met genotype affects complex emotion recognition in healthy men and women</article-title>. <source>Frontiers in Neuroscience</source><volume>12</volume>: <fpage>1007</fpage>.<pub-id pub-id-type="pmid">30723391</pub-id></mixed-citation>
              </ref>
              <ref id="bibr39-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovallo</surname><given-names>WR</given-names></name><name><surname>Enoch</surname><given-names>M-A</given-names></name><name><surname>Sorocco</surname><given-names>KH</given-names></name></person-group>, <etal>et al</etal>. (<year>2017</year>) <article-title>Joint impact of early life adversity and COMT Val158Met (rs4680) genotypes on the adult cortisol response to psychological stress</article-title>. <source>Psychosomatic Medicine</source><volume>79</volume>(<issue>6</issue>): <fpage>631</fpage>–<lpage>637</lpage>.<pub-id pub-id-type="pmid">28452825</pub-id></mixed-citation>
              </ref>
              <ref id="bibr40-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>MAG</given-names></name><name><surname>Kaltenboeck</surname><given-names>A</given-names></name><name><surname>Halahakoon</surname><given-names>DC</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>An experimental medicine investigation of the effects of subacute pramipexole treatment on emotional information processing in healthy volunteers</article-title>. <source>Pharmaceuticals</source><volume>14</volume>(<issue>8</issue>): <fpage>800</fpage>.<pub-id pub-id-type="pmid">34451897</pub-id></mixed-citation>
              </ref>
              <ref id="bibr41-02698811221089032">
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>McNair</surname><given-names>DM</given-names></name><name><surname>Lorr</surname><given-names>M</given-names></name><name><surname>Droppleman</surname><given-names>LF</given-names></name></person-group> (<year>1971</year>) <source>Manual Profile of Mood States</source>. <publisher-loc>San Diego, CA</publisher-loc>: <publisher-name>Educational and Industrial Testing Services</publisher-name>.</mixed-citation>
              </ref>
              <ref id="bibr42-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Lindenberg</surname><given-names>A</given-names></name><name><surname>Weinberger</surname><given-names>DR</given-names></name></person-group> (<year>2006</year>) <article-title>Intermediate phenotypes and genetic mechanisms of psychiatric disorders</article-title>. <source>Nature Reviews Neuroscience</source>
<volume>7</volume>(<issue>10</issue>): <fpage>818</fpage>–<lpage>827</lpage>.<pub-id pub-id-type="pmid">16988657</pub-id></mixed-citation>
              </ref>
              <ref id="bibr43-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mier</surname><given-names>D</given-names></name><name><surname>Kirsch</surname><given-names>P</given-names></name><name><surname>Meyer-Lindenberg</surname><given-names>A</given-names></name></person-group> (<year>2010</year>) <article-title>Neural substrates of pleiotropic action of genetic variation in COMT: A meta-analysis</article-title>. <source>Molecular Psychiatry</source>
<volume>15</volume>(<issue>9</issue>): <fpage>918</fpage>–<lpage>927</lpage>.<pub-id pub-id-type="pmid">19417742</pub-id></mixed-citation>
              </ref>
              <ref id="bibr44-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montag</surname><given-names>C</given-names></name><name><surname>Buckholtz</surname><given-names>JW</given-names></name><name><surname>Hartmann</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>. (<year>2008</year>) <article-title>COMT genetic variation affects fear processing: Psychophysiological evidence</article-title>. <source>Behavioral Neuroscience</source><volume>122</volume>(<issue>4</issue>): <fpage>901</fpage>–<lpage>909</lpage>.<pub-id pub-id-type="pmid">18729643</pub-id></mixed-citation>
              </ref>
              <ref id="bibr45-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opmeer</surname><given-names>EM</given-names></name><name><surname>Kortekaas</surname><given-names>R</given-names></name><name><surname>van Tol</surname><given-names>M-J</given-names></name></person-group>, <etal>et al</etal>. (<year>2013</year>) <article-title>Influence of COMT val158met genotype on the depressed brain during emotional processing and working memory</article-title>. <source>PLoS ONE</source><volume>8</volume>(<issue>9</issue>): e73290.</mixed-citation>
              </ref>
              <ref id="bibr46-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaleo</surname><given-names>F</given-names></name><name><surname>Crawley</surname><given-names>JN</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>2008</year>) <article-title>Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice</article-title>. <source>Journal of Neuroscience</source><volume>28</volume>(<issue>35</issue>): <fpage>8709</fpage>–<lpage>8723</lpage>.<pub-id pub-id-type="pmid">18753372</pub-id></mixed-citation>
              </ref>
              <ref id="bibr47-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pooley</surname><given-names>EC</given-names></name><name><surname>Fineberg</surname><given-names>N</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name></person-group> (<year>2007</year>) <article-title>The met158 allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: Case-control study and meta-analysis</article-title>. <source>Molecular Psychiatry</source>
<volume>12</volume>(<issue>6</issue>): <fpage>556</fpage>–<lpage>561</lpage>.<pub-id pub-id-type="pmid">17264842</pub-id></mixed-citation>
              </ref>
              <ref id="bibr48-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasch</surname><given-names>B</given-names></name><name><surname>Spalek</surname><given-names>K</given-names></name><name><surname>Buholzer</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2010</year>) <article-title>Aversive stimuli lead to differential amygdala activation and connectivity patterns depending on catechol-O-methyltransferase Val158Met genotype</article-title>. <source>NeuroImage</source><volume>52</volume>(<issue>4</issue>): <fpage>1712</fpage>–<lpage>1719</lpage>.<pub-id pub-id-type="pmid">20510373</pub-id></mixed-citation>
              </ref>
              <ref id="bibr49-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>B</given-names></name><name><surname>Blecha</surname><given-names>L</given-names></name><name><surname>Locatelli</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>. (<year>2018</year>) <article-title>Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety</article-title>. <source>Journal of Psychopharmacology</source><volume>32</volume>(<issue>4</issue>): <fpage>385</fpage>–<lpage>396</lpage>.<pub-id pub-id-type="pmid">29543103</pub-id></mixed-citation>
              </ref>
              <ref id="bibr50-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolka</surname><given-names>MN</given-names></name></person-group> (<year>2005</year>) <article-title>Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex</article-title>. <source>Journal of Neuroscience</source>
<volume>25</volume>(<issue>4</issue>): <fpage>836</fpage>–<lpage>842</lpage>.<pub-id pub-id-type="pmid">15673663</pub-id></mixed-citation>
              </ref>
              <ref id="bibr51-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolka</surname><given-names>MN</given-names></name><name><surname>Bühler</surname><given-names>M</given-names></name><name><surname>Schumann</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. (<year>2007</year>) <article-title>Gene–gene effects on central processing of aversive stimuli</article-title>. <source>Molecular Psychiatry</source><volume>12</volume>(<issue>3</issue>): <fpage>307</fpage>–<lpage>317</lpage>.<pub-id pub-id-type="pmid">17211439</pub-id></mixed-citation>
              </ref>
              <ref id="bibr52-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soeiro-de-Souza</surname><given-names>MG</given-names></name><name><surname>Bio</surname><given-names>DS</given-names></name><name><surname>David</surname><given-names>DP</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>COMT Met (158) modulates facial emotion recognition in bipolar I disorder mood episodes</article-title>. <source>Journal of Affective Disorders</source><volume>136</volume>(<issue>3</issue>): <fpage>370</fpage>–<lpage>376</lpage>.<pub-id pub-id-type="pmid">22222175</pub-id></mixed-citation>
              </ref>
              <ref id="bibr53-02698811221089032">
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spielberger</surname><given-names>CD</given-names></name></person-group> (<year>1983</year>) <source>State-Trait Anxiety Inventory for Adults</source>. <publisher-loc>Palo Alto, CA</publisher-loc>: <publisher-name>Consulting Psychologists Press</publisher-name>.</mixed-citation>
              </ref>
              <ref id="bibr54-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>DePasquale</surname><given-names>M</given-names></name><name><surname>Liao</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. (<year>2021</year>) <article-title>Membrane bound catechol-O-methytransferase is the dominant isoform for dopamine metabolism in PC12 cells and rat brain</article-title>. <source>European Journal of Pharmacology</source><volume>896</volume>: <fpage>173909</fpage>.<pub-id pub-id-type="pmid">33503461</pub-id></mixed-citation>
              </ref>
              <ref id="bibr55-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surguladze</surname><given-names>SA</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name><name><surname>El-Hage</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>Interaction of catechol O-methyltransferase and serotonin transporter genes modulates effective connectivity in a facial emotion-processing circuitry</article-title>. <source>Translational Psychiatry</source><volume>2</volume>(<issue>1</issue>): e70.</mixed-citation>
              </ref>
              <ref id="bibr56-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamm</surname><given-names>G</given-names></name><name><surname>Kreegipuu</surname><given-names>K</given-names></name><name><surname>Harro</surname><given-names>J</given-names></name></person-group> (<year>2016</year>) <article-title>Perception of emotion in facial stimuli: The interaction of ADRA2A and COMT genotypes, and sex</article-title>. <source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source>
<volume>64</volume>: <fpage>87</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">26234518</pub-id></mixed-citation>
              </ref>
              <ref id="bibr57-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>H-Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Sust</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2007</year>) <article-title>Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function</article-title>. <source>Proceedings of the National Academy of Sciences</source><volume>104</volume>(<issue>30</issue>): <fpage>12536</fpage>–<lpage>12541</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr58-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troudet</surname><given-names>R</given-names></name><name><surname>Detrait</surname><given-names>E</given-names></name><name><surname>Hanon</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal>. (<year>2016</year>) <article-title>Optimization and pharmacological validation of a set-shifting procedure for assessing executive function in rats</article-title>. <source>Journal of Neuroscience Methods</source><volume>268</volume>: <fpage>182</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">26296285</pub-id></mixed-citation>
              </ref>
              <ref id="bibr59-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>AM</given-names></name><name><surname>Farrell</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>. (<year>2012</year>) <article-title>The role of catechol-O-methyltransferase in reward processing and addiction</article-title>. <source>CNS &amp; Neurological Disorders – Drug Targets</source><volume>11</volume>(<issue>3</issue>): <fpage>306</fpage>–<lpage>323</lpage>.<pub-id pub-id-type="pmid">22483300</pub-id></mixed-citation>
              </ref>
              <ref id="bibr60-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>E</given-names></name><name><surname>Weickert</surname><given-names>C</given-names></name><name><surname>Kleinman</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. (<year>2007</year>) <article-title>Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan</article-title>. <source>Cerebral Cortex</source><volume>17</volume>(<issue>5</issue>): <fpage>1206</fpage>–<lpage>1212</lpage>.<pub-id pub-id-type="pmid">16835293</pub-id></mixed-citation>
              </ref>
              <ref id="bibr61-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>EM</given-names></name></person-group> (<year>2004</year>) <article-title>Catechol-O-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex</article-title>. <source>Journal of Neuroscience</source>
<volume>24</volume>(<issue>23</issue>): <fpage>5331</fpage>–<lpage>5335</lpage>.<pub-id pub-id-type="pmid">15190105</pub-id></mixed-citation>
              </ref>
              <ref id="bibr62-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>EM</given-names></name><name><surname>Narajos</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>CH</given-names></name></person-group>, <etal>et al</etal>. (<year>2019</year>) <article-title>Which dopamine polymorphisms are functional? Systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1–5, MAOA, MAOB, TH, VMAT1, and VMAT2</article-title>. <source>Biological Psychiatry</source><volume>86</volume>(<issue>8</issue>): <fpage>608</fpage>–<lpage>620</lpage>.<pub-id pub-id-type="pmid">31303260</pub-id></mixed-citation>
              </ref>
              <ref id="bibr63-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vai</surname><given-names>B</given-names></name><name><surname>Riberto</surname><given-names>M</given-names></name><name><surname>Ghiglino</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>. (<year>2017</year>) <article-title>A 5-HT1A receptor promoter polymorphism influences fronto-limbic functional connectivity and depression severity in bipolar disorder</article-title>. <source>Psychiatry Research: Neuroimaging</source><volume>270</volume>: <fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">28985530</pub-id></mixed-citation>
              </ref>
              <ref id="bibr64-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>EM</given-names></name><name><surname>Stadelmann</surname><given-names>E</given-names></name><name><surname>Kohler</surname><given-names>CG</given-names></name></person-group>, <etal>et al</etal>. (<year>2007</year>) <article-title>Differential effect of catechol-O-methyltransferase Val158Met genotype on emotional recognition abilities in healthy men and women</article-title>. <source>Journal of the International Neuropsychological Society</source><volume>13</volume>(<issue>5</issue>): <fpage>881</fpage>–<lpage>887</lpage>.<pub-id pub-id-type="pmid">17517149</pub-id></mixed-citation>
              </ref>
              <ref id="bibr65-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>GV</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group> (<year>1995</year>) <article-title>Modulation of memory fields by dopamine Dl receptors in prefrontal cortex</article-title>. <source>Nature</source>
<volume>376</volume>(<issue>6541</issue>): <fpage>572</fpage>–<lpage>575</lpage>.<pub-id pub-id-type="pmid">7637804</pub-id></mixed-citation>
              </ref>
              <ref id="bibr66-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>LM</given-names></name><name><surname>Gatt</surname><given-names>JM</given-names></name><name><surname>Grieve</surname><given-names>SM</given-names></name></person-group>, <etal>et al</etal>. (<year>2010</year>) <article-title>COMT Val108/158Met polymorphism effects on emotional brain function and negativity bias</article-title>. <source>NeuroImage</source><volume>53</volume>(<issue>3</issue>): <fpage>918</fpage>–<lpage>925</lpage>.<pub-id pub-id-type="pmid">20139013</pub-id></mixed-citation>
              </ref>
              <ref id="bibr67-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AW</given-names></name><name><surname>Rowland</surname><given-names>D</given-names></name><name><surname>Calder</surname><given-names>AJ</given-names></name></person-group>, <etal>et al</etal>. (<year>1997</year>) <article-title>Facial expression megamix: Tests of dimensional and category accounts of emotion recognition</article-title>. <source>Cognition</source><volume>63</volume>(<issue>3</issue>): <fpage>271</fpage>–<lpage>313</lpage>.<pub-id pub-id-type="pmid">9265872</pub-id></mixed-citation>
              </ref>
              <ref id="bibr68-02698811221089032">
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zürcher</surname><given-names>G</given-names></name><name><surname>Colzi</surname><given-names>A</given-names></name><name><surname>Da Prada</surname><given-names>M</given-names></name></person-group> (<year>1990</year>) <article-title>Ro 40-7592: Inhibition of COMT in rat brain and extracerebral tissues</article-title>. <source>Journal of Neural Transmission</source>
<volume>32</volume>: <fpage>375</fpage>–<lpage>380</lpage>.<pub-id pub-id-type="pmid">2089102</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
